In the present study, we investigated the clinical effects of image-guided iodine-125 (125I) seed on unresectable pancreatic cancer. Twenty-five patients with unresectable pancreatic cancer were enrolled in this study, including 13 patients with seed implantation and 12 patients as control. The survival status, clinical benefits, objective curative effects, and relevant tumor markers were analyzed to assess the feasibility and safety of interstitial 125I seed implantation. We found that the clinical benefit rate of the seed implantation group is 92.3 % (12/13), compared with 41.7 % (5/12) in the control, and the difference was statistically significant (p < 0.01). Compared with control, patients with seed implantation had significantly shorter operative time, less bleeding, higher albumin, shorter periods to bowel movement, and normal diet as well as lower risk of complications (p < 0.001). The differences of objective curative effects adverse effects, complications, and median survival between these two groups were not significant statistically (p > 0.05). In conclusion, 125I seed implantation provides a safe and effective method to inhibit the tumor development, relieve pain, and improve quality of life for unresectable pancreatic cancer. These findings need to be validated by conducting further studies with larger cohorts.
Image-guided 125I seed Utility Unresectable pancreatic cancer
This is a preview of subscription content, log in to check access.
We gratefully thank other members of Yang Lab for their critical reading of this paper and valuable suggestions.
Baron TH, Kozarek RA. Preoperative biliary stents in pancreatic cancer-proceed with caution. N Engl J Med. 2010;362(2):170–2.CrossRefPubMedGoogle Scholar
Furuse J, Kinoshita T, Kawashima M, et al. Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer. 2003;97:1346–52.CrossRefPubMedGoogle Scholar
Wang JJ, Jiang YL, Li JN, et al. Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res. 2009;28:1–6.CrossRefGoogle Scholar
Wang H, Wang J, Jiang Y, et al. The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma. J Exp Clin Cancer Res. 2013;32(1):106.CrossRefPubMedPubMedCentralGoogle Scholar
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer. 2009;45:228–47.CrossRefPubMedGoogle Scholar
Watanabe H, Okada M, Kaji Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline. Gan To Kagaku Ryoho. 2009;36(13):2495–501.PubMedGoogle Scholar
Liang J, Xi JW, Pan HJ, et al. Effect and mechanism of 125I radioactive particles interposed radiotherapy between organizations on lung cancer. Chin-Ger J Clin Oncol. 2013;12(12):1245–4.CrossRefGoogle Scholar
Ma JX, Jin ZD, Si PR, et al. Continuous and low-energy 125I seed irradiation changes DNA methyltransferases expression patterns and inhibits pancreatic cancer tumor growth. J Exp Clin Cancer Res. 2011;30:35.CrossRefPubMedPubMedCentralGoogle Scholar
Ma ZH, Yang Y, Zou L, et al. 125I seed irradiation induces upregulation of the genes associated with apoptosis and cell cycle arrest and inhibits growth of gastric cancer xenografts. J Exp Clin Cancer Res. 2012;31:61.CrossRefPubMedPubMedCentralGoogle Scholar
Syed AM, Puthawala AA, Neblett DL. Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma. Cancer. 1983;52:808–13.CrossRefPubMedGoogle Scholar
Liu K, Zhang W, Liu SY, et al. Comparison of iodine-125 seed implantation and pancreaticoduodenectomy in the treatment of pancreatic cancer. Int J Med Sci. 2014;11(9):893–6.CrossRefPubMedPubMedCentralGoogle Scholar
Wang ZM, Liu Y, Liu FJ, et al. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer. Eur Radiol. 2010;20(7):1786–91.CrossRefGoogle Scholar
Ioka T, Nakamura S, Nishiyama K. A randomized phase II study of gemcitabine 1000 mg/msq and concurrent radiotherapy comparing gemcitabine alone for unresectable locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2010;78:S102.CrossRefGoogle Scholar
Peretz T, Nori D, Hilaris B, et al. Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys. 1989;17:931–5.CrossRefPubMedGoogle Scholar